Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate, RLY5016, is a non- absorbed potassium binder for the treatment of hyperkalemia and is currently being tested in a pivotal phase 3 clinical study. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. Privately-held, Relypsa’s investors include: OrbiMed, 5AM Ventures, Delphi Ventures, Mediphase Venture Partners, New Leaf Venture Partners, Sprout Group, Amgen and Sibling Capital.

May 15, 2013 ^NEW
Relypsa Announces Appointment of John Orwin as Chief Executive Officer

May 13, 2013
Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia